Veristat Names Kim McLean Boericke as CEO

Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, has named Kim McLean Boericke as its Chief Executive Officer (CEO).

Boericke, an experienced executive with decades of leadership and operational experience in the clinical research industry, succeeds Patrick Flanagan, who will transition to Veristat’s Board of Directors.

“I’m delighted to pass the baton to Kim at this exciting time for the company. She is a scientifically astute leader with high-quality standards and a record of success,” said Flanagan.

As CEO, Boericke will focus on building upon Veristat’s evolution toward becoming a leader in providing data analytics and insights to their clients and supporting global, approvable regulatory submissions. Specifically, she aims to expand Veristat’s therapeutic specialization in oncology, neurology, and rare diseases, ensuring the organization is well-positioned to support clients in advancing innovative therapies to patients with unmet medical needs worldwide.

Experience

Boericke, who was previously Veristat’s Chief Operating Officer, brings more than 25 years of industry experience and represents a minority of female executives in the life sciences industry.

She previously held executive-level positions at Thread, ICON, IQVIA, i3 Research, and INC Research, playing pivotal roles advising, planning, and delivering on clinical development programs. In addition, Boericke has been an active board member for MAPI Trust, both as Chairwoman and as Independent Director.

“Veristat is at the forefront of clinical research, and I’m excited to continue building on our company’s vision to help bring the most advanced therapies to patients,” said Boericke. “My immediate focus will be on expanding Veristat’s early-stage strategic consulting capabilities, enabling closer collaboration with clients to finalize and deliver drug development programs, optimize clinical trial design, and streamline regulatory pathways to approval.”